Seeking Alpha

Celgene (CELG) says 52-week results demonstrate apremilast produces "meaningful improvements" in...

Celgene (CELG) says 52-week results demonstrate apremilast produces "meaningful improvements" in ACR scores for patients with psoriatic arthritis. The company will present the data at the European Congress of Rheumatology later today. SA contributor Todd Campbell says the drug "offers upside" for CELG shares and notes that "analysts expect apremilast may generate sales of $300-500M/year." Shares +1.5% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector